Donaldson Capital Management LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Donaldson Capital Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% in the third quarter, Holdings Channel reports. The institutional investor owned 196,314 shares of the company’s stock after selling 11,819 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Donaldson Capital Management LLC’s holdings, making the stock its 26th biggest position. Donaldson Capital Management LLC’s holdings in Johnson & Johnson were worth $25,399,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the business. WoodTrust Financial Corp increased its position in Johnson & Johnson by 4.2% during the third quarter. WoodTrust Financial Corp now owns 46,335 shares of the company’s stock valued at $5,995,000 after acquiring an additional 1,848 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in Johnson & Johnson during the third quarter valued at $2,939,000. Billeaud Capital Management Inc. increased its position in Johnson & Johnson by 0.4% during the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares during the last quarter. Meeder Asset Management Inc. increased its position in Johnson & Johnson by 11.1% during the second quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after acquiring an additional 10,927 shares during the last quarter. Finally, Lucia Wealth Services LLC increased its position in Johnson & Johnson by 2.1% during the third quarter. Lucia Wealth Services LLC now owns 131,950 shares of the company’s stock valued at $17,072,000 after acquiring an additional 2,744 shares during the last quarter. Institutional investors and hedge funds own 72.22% of the company’s stock.

A number of research firms recently commented on JNJ. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a research report on Thursday, October 17th. Raymond James reduced their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Friday, October 11th. Credit Suisse Group upped their price objective on Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Finally, Wells Fargo & Co reduced their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $151.64.

NYSE:JNJ traded up $0.02 during mid-day trading on Wednesday, hitting $131.37. 1,990,628 shares of the company traded hands, compared to its average volume of 7,202,121. The firm has a market cap of $350.04 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 2.25 and a beta of 0.69. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The stock’s fifty day moving average price is $130.88 and its 200-day moving average price is $133.96. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. During the same period in the prior year, the company earned $2.05 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 8.65 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is presently 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: How to identify percentage decliners

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.